

September 27, 2023

Τo

Listing Department.

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001**

Company Code No. 524804

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform that Auro Vaccines Private Limited, a wholly owned subsidiary of the Company, has today, September 27, 2023, entered into a Licence Agreement with Hilleman Laboratories Singapore Pte. Limited to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination. Auro Vaccines Private Limited will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate.

Please note that Auro Vaccines Private Limited is not a material subsidiary to the Company and the aforesaid entry into a Licence Agreement is not a material event. It may also be noted that at present entering into the aforesaid Licence Agreement will not have any significant impact on the Company and/or its subsidiaries or its financials. In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures.

This is for your information and records.

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.